参柴舒心汤治疗冠心病心绞痛合并焦虑症临床疗效观察

发布时间：2018-04-26 07:37

本文选题：参柴舒心汤 + 稳定性心绞痛　；参考：《黑龙江中医药大学》2017年硕士论文

【摘要】：目的:观察参柴舒心汤治疗冠心病稳定性心绞痛(气滞血瘀证)合并焦虑症患者临床疗效,探讨其治疗冠心病的有效性、安全性及对合并焦虑症的改善情况。方法:将60例确诊为冠心病稳定性心绞痛(气滞血瘀证)合并焦虑症患者随机分为治疗组和对照组,每组各30例;对照组给予西医常规基础治疗及心理疏导,治疗组在对照组基础上给予参柴舒心汤,疗程为4周;观察治疗前后两组患者心绞痛症状、中医症状、心电图、硝酸甘油停减率、西雅图心绞痛量表、汉密尔顿焦虑量表的变化情况,利用SPSS20.0统计学软件对数据进行分析。结果:1.治疗后,治疗组心绞痛积分、中医证候积分低于对照组,差异均有统计学意义(p0.05);两组心绞痛积分、中医证候积分均比治疗前降低,差异均有统计学意义(p0.05)。2.治疗组心绞痛疗效和中医证候疗效的总有效率均高于对照组,差异均有统计学意义(p0.05)。3.在心电图疗效方面,治疗组总有效率为46.67%,对照组总有效率为33.33%,差异无统计学意义(p0.05)。4.在硝酸甘油停减率方面,治疗组为73.33%,对照组为46.67%,差异有统计学意义(p0.05)。5.治疗后,治疗组在SAQ五大项评分方面均高于对照组,差异均有统计学意义(p0.05);治疗后,治疗组上述评分均高于治疗前水平,差异均有统计学意义(p0.05);对照组除AS项外,余各项评分均高于治疗前水平,差异均有统计学意义(p0.05)。6.治疗后,治疗组HAMA评分低于对照组,差异有统计学意义(p0.05);治疗后两组量表评分均低于治疗前水平,差异均有统计学意义(p0.05);治疗组疗效总有效率高于对照组,差异有统计学意义 (p0.05)。结论:1.参柴舒心汤能够缓解气滞血瘀证稳定性心绞痛合并焦虑症患者的心绞痛症状,改善中医证候。2.参柴舒心汤能够提高气滞血瘀证稳定性心绞痛合并焦虑症患者的生活质量。3.参柴舒心汤能够改善气滞血瘀证稳定性心绞痛合并焦虑症患者的焦虑症状。
[Abstract]:Objective: to observe the clinical effect of Shenchaishuxin decoction in the treatment of stable angina pectoris (Qi stagnation and blood stasis syndrome) with anxiety disorder, and to explore the efficacy, safety and improvement of Shenchaishuxin decoction in the treatment of coronary heart disease. Methods: sixty patients with stable angina pectoris of coronary heart disease (Qi stagnation and blood stasis syndrome) and anxiety disorder were randomly divided into treatment group and control group with 30 cases in each group. The treatment group was treated with Shenchaisuxin decoction for 4 weeks on the basis of the control group, and the symptoms of angina pectoris, symptoms of TCM, ECG, reduction rate of nitroglycerin and Seattle angina scale were observed before and after treatment. The changes of Hamilton anxiety scale were analyzed by SPSS20.0 software. The result is 1: 1. After treatment, the scores of angina pectoris and TCM syndromes in the treatment group were lower than those in the control group, the differences were statistically significant (P 0.05), and the scores of angina pectoris and TCM syndromes in the two groups were lower than those before treatment, and the differences were statistically significant. The total effective rate of angina pectoris and TCM syndromes in the treatment group was higher than that in the control group, and the difference was statistically significant. The total effective rate of electrocardiogram was 46.67 in the treatment group and 33.33 in the control group. The stopping rate of nitroglycerin was 73.33 in the treatment group and 46.67 in the control group. The difference was statistically significant. After treatment, the scores of five items of SAQ in the treatment group were higher than those in the control group, the differences were statistically significant (P 0.05), and after treatment, the scores in the treatment group were all higher than those before treatment, and the differences were statistically significant (P 0.05). The remaining scores were higher than those before treatment, and the differences were statistically significant. After treatment, the HAMA score in the treatment group was lower than that in the control group, the difference was statistically significant (P 0.05), the score of the two groups was lower than that before treatment, and the difference was statistically significant (P 0.05). The total effective rate of the treatment group was higher than that of the control group. The difference was statistically significant (P 0.05). Conclusion 1. ShenchaiShuxin decoction can relieve the symptoms of angina pectoris associated with anxiety in patients with stable angina pectoris and improve TCM syndromes. ShenchaiShuxin decoction can improve the quality of life of patients with stable angina pectoris complicated with anxiety syndrome of qi stagnation and blood stasis syndrome. ShenchaiShuxin decoction can improve the anxiety symptoms of patients with stable angina pectoris and anxiety syndrome of qi stagnation and blood stasis syndrome.
【学位授予单位】：黑龙江中医药大学
【学位级别】：硕士
【学位授予年份】：2017
【分类号】：R541.4;R749.72

【相似文献】